Novaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain
21.12.2021 17:47:00 EET | Business Wire | Press release
Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces a study with the National Institutes of Health (NIH) under which the NIH will sponsor and conduct a clinical Phase 2b study with Novaremed’s lead non-opioid development compound NRD.E1 in the treatment of painful diabetic peripheral neuropathy (PDPN).
After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN. For this phase 2 investigational trial, Novaremed will provide drug supply and EPPIC-Net (Early Phase Pain Investigation Clinical Network), which is part of the NIH HEAL Initiative, will run the study in the United States.
The NIH-supported Phase 2b trial EN21-01, named SERENDIPITY-1, is a 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of NRD.E1 versus placebo in 260 adult and elderly patients with PDNP. The primary efficacy endpoint aims to demonstrate superiority of NRD.E1 compared to placebo in relieving PDPN. The secondary objectives of the study are to evaluate the pharmacokinetics, safety, and tolerability of NRD.E1, and assess several additional endpoints, including the effect of NRD.E1 on sleep and quality-of-life indicators. The study is planned to start in the second quarter of 2022.
“We are delighted about the NIH support for our lead development candidate NRD.E1,” said Isaac Kobrin, MD, Executive Chairman of the Board of Novaremed. “Currently, approved medications for PDPN provide inadequate pain relief and are associated with many intolerable side effects. We view the funding from the NIH as both an acknowledgment of the validity of the efficacy data and the favorable tolerability and safety profile, as demonstrated in the Phase 2a proof-of-concept study, and a recognition of the high unmet medical need for safe and effective therapies for patients with PDPN.”
“Based on clinical data from the proof-of-concept study and its novel mode of action, we believe that NRD.E1 has the potential to offer unique benefits for treating neuropathic pain associated with diabetes while avoiding some of the side effects observed with current therapies, which often limit their use,” said Eva Tiecke, PhD, Chief Scientific Officer and Head of R&D of Novaremed. “We are thankful to the NIH team for advancing the project to this exciting milestone and look forward to continued collaboration to study this compound.”
About NRD.E1
NRD.E1 (or NRD135S.E1), an orally active small molecule with a novel mechanism of action, is the Company’s lead compound being developed to treat PDPN. The mechanism of action of NRD.E1 is different to that of approved pain therapies as it does not bind to opioid receptors or other known receptors associated with pain. Completed clinical studies with NRD.E1 include Phase 1 studies and a Phase 2a proof-of-concept study (ClinicalTrials.gov identifier: NCT02345291), which was a 3-week, dose-finding, placebo-controlled, randomized, multi-center study in 86 patients with moderate to severe PDPN and compared three doses (10, 40 and 150 mg/day) of NRD.E1 to placebo. Results showed a clinically relevant, dose-related pain reduction and a favorable tolerability profile of NRD.E1 at all tested doses. Moreover, the results suggested similar or greater pain relief, and better tolerability than reported for standard approved therapies. The US FDA approved the IND for the Phase 2b trial and granted Fast Track Designation to NRD.E1 for the treatment of PDPN.
Reference:
[1] Tiecke et al., NRD.E1, An Innovative Non-Opioid Therapy for Painful Diabetic Peripheral Neuropathy – A Randomised Proof of Concept Study, submitted to the European Journal of Pain
About NIH, NIH-HEAL and EPPIC-Net
The US National Institutes of Health (NIH), the largest biomedical research agency in the world, has established the NIH HEAL Initiative® to address the opioid crisis. HEAL programs include those focused on identifying, developing, and testing new non-addictive pain therapies. The EPPIC-Net (Early Phase Pain Investigation Clinical Network) is part of the NIH HEAL Initiative and seeks to enhance the treatment of acute and chronic pain and reduce reliance on opioids by accelerating early-phase clinical trials of non-addictive treatments for pain. For more information: https://heal.nih.gov
About peripheral neuropathy and associated neuropathic pain
Peripheral nerve injury from various etiologies may ultimately result in chronic and severe intractable neuropathic pain. Painful diabetic peripheral neuropathy (PDPN) and chemotherapy-induced peripheral neuropathy (CIPN) are frequent complications of diabetes and cancer treatment and represent the most common forms of neuropathic pain with a high unmet medical need. Worldwide, two-thirds or an estimated 8.1 million diabetes patients with PDPN requiring treatment do not obtain substantial pain relief with current therapies. Many of the currently available products for the treatment of chronic neuropathic pain have limited efficacy and are often not well tolerated. The increasing prevalence of diabetes and cancer as well as the limitations of the available therapies make the prevention and treatment of chronic neuropathic pain a condition of high unmet medical need.
About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic pain includes the development candidates MP-101 (Phase 2 stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). Currently, over 80% or about 3.1 million cancer patients receiving neurotoxic chemotherapy develop CIPN, which is a leading cause for therapy reduction and/or discontinuation, as well as having a significant impact on patients’ quality of life.
Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005476/en/
Contact information
Mark Altmeyer, Executive Member of the Board
mark.altmeyer@novaremed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 15:08:00 EET | Press release
Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 15:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119117575/en/ Representative pre- and post-mangaciclanol images in patients from the LUMINA Phase 2/3 trial
Ehime CATV expands public-sector connectivity in Japan with Adtran XGS-PON technology19.11.2026 15:00:00 EET | Press release
Adtran today announced that Ehime CATV has selected its XGS-PON technology to support a new broadband network for public schools and local government offices in Ehime Prefecture, Japan. The deployment will provide 10Gbit/s connectivity to more than 100 public-sector sites, supporting digital learning, cloud-based applications and everyday online services for students, teachers and municipal users. With its compact footprint and flexible expansion model, Adtran’s access technology will help Ehime CATV transition beyond legacy EPON infrastructure to ITU-based XGS-PON. The upgrade will also support a more diversified supplier strategy, helping mitigate geopolitical supply chain risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119028160/en/ Adtran’s XGS-PON technology is helping Ehime CATV develop a new broadband network for public schools and local government offices. “Supporting the communities we serve has always been
Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 15:00:00 EET | Press release
Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release
At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
